High-risk acute promyelocytic leukemia with unusual T/myeloid immunophenotype successfully treated with ATRA and arsenic trioxide-based regimen

Zeba N. Singh, Vu H. Duong, Rima Koka, Ying Zou, Sameer Sawhney, Li Tang, Maria R. Baer, Nicholas Ambulos, Firas El Chaer, Ashkan Emadi

Research output: Contribution to journalArticle

Abstract

We describe two patients with acute promyelocytic leukemia (APL) with an unusual immunophenotype with co-expression of myeloperoxidase (MPO) with cytoplasmic CD3 (cCD3) representing myeloid and T-lineage differentiation. Both harbored FLT3-ITD mutations. One additionally had a deletion in the PML gene affecting the primer binding site, thus limiting measurable residual disease (MRD) analysis during follow-up. Both patients achieved durable remission with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO)-based therapy, thus mitigating the need for repetitive conventional chemotherapy cycles and allogeneic stem cell transplantation. Our report highlights the complexity and challenge of diagnosis and management of APL due to the variant immunophenotype and genetics and underscores the importance of synthesizing information from all testing modalities. The association of the unusual immunophenotype and FLT3-ITD mutation illustrates the plasticity of the hematopoietic stem cell and the pathobiology of leukemia with mixed lineage or lineage infidelity.

Original languageEnglish (US)
Pages (from-to)67-74
Number of pages8
JournalJournal of Hematopathology
Volume11
Issue number3
DOIs
StatePublished - Sep 1 2018
Externally publishedYes

Fingerprint

Acute Promyelocytic Leukemia
Tretinoin
Mutation
Stem Cell Transplantation
Hematopoietic Stem Cells
Peroxidase
Leukemia
Binding Sites
Drug Therapy
Genes
arsenic trioxide
Therapeutics

Keywords

  • Acute promyelocytic leukemia (APL)
  • All-trans retinoic acid (ATRA)
  • Arsenic trioxide (ATO)
  • Measurable (minimal) residual disease (MRD)
  • Mixed phenotype acute leukemia (MPAL)

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Hematology

Cite this

High-risk acute promyelocytic leukemia with unusual T/myeloid immunophenotype successfully treated with ATRA and arsenic trioxide-based regimen. / Singh, Zeba N.; Duong, Vu H.; Koka, Rima; Zou, Ying; Sawhney, Sameer; Tang, Li; Baer, Maria R.; Ambulos, Nicholas; El Chaer, Firas; Emadi, Ashkan.

In: Journal of Hematopathology, Vol. 11, No. 3, 01.09.2018, p. 67-74.

Research output: Contribution to journalArticle

Singh, Zeba N. ; Duong, Vu H. ; Koka, Rima ; Zou, Ying ; Sawhney, Sameer ; Tang, Li ; Baer, Maria R. ; Ambulos, Nicholas ; El Chaer, Firas ; Emadi, Ashkan. / High-risk acute promyelocytic leukemia with unusual T/myeloid immunophenotype successfully treated with ATRA and arsenic trioxide-based regimen. In: Journal of Hematopathology. 2018 ; Vol. 11, No. 3. pp. 67-74.
@article{b644825edc5146b78bac5c5019f96c50,
title = "High-risk acute promyelocytic leukemia with unusual T/myeloid immunophenotype successfully treated with ATRA and arsenic trioxide-based regimen",
abstract = "We describe two patients with acute promyelocytic leukemia (APL) with an unusual immunophenotype with co-expression of myeloperoxidase (MPO) with cytoplasmic CD3 (cCD3) representing myeloid and T-lineage differentiation. Both harbored FLT3-ITD mutations. One additionally had a deletion in the PML gene affecting the primer binding site, thus limiting measurable residual disease (MRD) analysis during follow-up. Both patients achieved durable remission with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO)-based therapy, thus mitigating the need for repetitive conventional chemotherapy cycles and allogeneic stem cell transplantation. Our report highlights the complexity and challenge of diagnosis and management of APL due to the variant immunophenotype and genetics and underscores the importance of synthesizing information from all testing modalities. The association of the unusual immunophenotype and FLT3-ITD mutation illustrates the plasticity of the hematopoietic stem cell and the pathobiology of leukemia with mixed lineage or lineage infidelity.",
keywords = "Acute promyelocytic leukemia (APL), All-trans retinoic acid (ATRA), Arsenic trioxide (ATO), Measurable (minimal) residual disease (MRD), Mixed phenotype acute leukemia (MPAL)",
author = "Singh, {Zeba N.} and Duong, {Vu H.} and Rima Koka and Ying Zou and Sameer Sawhney and Li Tang and Baer, {Maria R.} and Nicholas Ambulos and {El Chaer}, Firas and Ashkan Emadi",
year = "2018",
month = "9",
day = "1",
doi = "10.1007/s12308-018-0329-z",
language = "English (US)",
volume = "11",
pages = "67--74",
journal = "Journal of Hematopathology",
issn = "1865-5785",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - High-risk acute promyelocytic leukemia with unusual T/myeloid immunophenotype successfully treated with ATRA and arsenic trioxide-based regimen

AU - Singh, Zeba N.

AU - Duong, Vu H.

AU - Koka, Rima

AU - Zou, Ying

AU - Sawhney, Sameer

AU - Tang, Li

AU - Baer, Maria R.

AU - Ambulos, Nicholas

AU - El Chaer, Firas

AU - Emadi, Ashkan

PY - 2018/9/1

Y1 - 2018/9/1

N2 - We describe two patients with acute promyelocytic leukemia (APL) with an unusual immunophenotype with co-expression of myeloperoxidase (MPO) with cytoplasmic CD3 (cCD3) representing myeloid and T-lineage differentiation. Both harbored FLT3-ITD mutations. One additionally had a deletion in the PML gene affecting the primer binding site, thus limiting measurable residual disease (MRD) analysis during follow-up. Both patients achieved durable remission with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO)-based therapy, thus mitigating the need for repetitive conventional chemotherapy cycles and allogeneic stem cell transplantation. Our report highlights the complexity and challenge of diagnosis and management of APL due to the variant immunophenotype and genetics and underscores the importance of synthesizing information from all testing modalities. The association of the unusual immunophenotype and FLT3-ITD mutation illustrates the plasticity of the hematopoietic stem cell and the pathobiology of leukemia with mixed lineage or lineage infidelity.

AB - We describe two patients with acute promyelocytic leukemia (APL) with an unusual immunophenotype with co-expression of myeloperoxidase (MPO) with cytoplasmic CD3 (cCD3) representing myeloid and T-lineage differentiation. Both harbored FLT3-ITD mutations. One additionally had a deletion in the PML gene affecting the primer binding site, thus limiting measurable residual disease (MRD) analysis during follow-up. Both patients achieved durable remission with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO)-based therapy, thus mitigating the need for repetitive conventional chemotherapy cycles and allogeneic stem cell transplantation. Our report highlights the complexity and challenge of diagnosis and management of APL due to the variant immunophenotype and genetics and underscores the importance of synthesizing information from all testing modalities. The association of the unusual immunophenotype and FLT3-ITD mutation illustrates the plasticity of the hematopoietic stem cell and the pathobiology of leukemia with mixed lineage or lineage infidelity.

KW - Acute promyelocytic leukemia (APL)

KW - All-trans retinoic acid (ATRA)

KW - Arsenic trioxide (ATO)

KW - Measurable (minimal) residual disease (MRD)

KW - Mixed phenotype acute leukemia (MPAL)

UR - http://www.scopus.com/inward/record.url?scp=85052694265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052694265&partnerID=8YFLogxK

U2 - 10.1007/s12308-018-0329-z

DO - 10.1007/s12308-018-0329-z

M3 - Article

VL - 11

SP - 67

EP - 74

JO - Journal of Hematopathology

JF - Journal of Hematopathology

SN - 1865-5785

IS - 3

ER -